Advancing Understanding of Treatment Through Clinical Trials
Saturday, November 3, 2012 - 22:30
in Health & Medicine
* Aliskiren on top of standard therapy does not seem to help type 2 diabetic patients at high risk for developing heart and kidney problems. * Tolvaptan benefits patients with autosomal dominant polycystic kidney disease. * Cinacalcet does not significantly reduce the risk of premature death or major heart-related events in dialysis patients with secondary hyperparathyroidism.